Oculis (NASDAQ:OCS) Stock Price Down 5.2% – Here’s Why

Oculis Holding AG (NASDAQ:OCS)’s share price fell 5.2% during trading on Friday . The stock traded as low as $29.45 and last traded at $29.38. 322,560 shares traded hands during mid-day trading, a decline of 10% from the average session volume of 356,983 shares. The stock had previously closed at $31.00.

Analyst Upgrades and Downgrades

A number of research firms have commented on OCS. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright raised their price target on Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. JPMorgan Chase & Co. lifted their price objective on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Needham & Company LLC increased their price target on Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $49.38.

Oculis Trading Down 5.0%

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The business has a 50 day moving average of $27.44 and a 200 day moving average of $24.83. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -13.83 and a beta of 0.38.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, research analysts predict that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OCS. Geode Capital Management LLC raised its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Oculis in the second quarter valued at about $393,000. Bank of America Corp DE increased its stake in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the period. Woodline Partners LP increased its stake in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares during the period. Finally, Aventura Private Wealth LLC acquired a new stake in shares of Oculis in the fourth quarter valued at about $80,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.